Breast Tumor Cells
Breast tumors are among the most extensively studied solid malignancies, characterized by significant heterogeneity in histology, molecular subtypes, and clinical behavior. Based on hormone receptor and HER2 status, breast cancers are commonly classified into luminal, HER2-positive, and triple-negative subtypes, each associated with distinct biological features and therapeutic responses.
Our breast tumor cell line collection provides well-established in vitro models representing these major subtypes, supporting studies on tumor biology, endocrine response, metastasis, and targeted therapy development across diverse breast cancer contexts.
Reliable Authentic Diverse Supported
Key Features & Expertise
Our breast tumor cell lines are tailored for comprehensive breast cancer research
Representation of Major Breast Cancer Subtypes
- Includes luminal (ER/PR-positive), HER2-positive, and triple-negative models
- Reflect clinically relevant classifications used in diagnosis and treatment
- Supports subtype-specific research and therapeutic evaluation
Molecularly Defined and Functionally Relevant
- Characterized by key biomarkers such as ER, PR, and HER2 expression
- Harbor common mutations including TP53, PIK3CA, and BRCA-related alterations
- Suitable for studies on signaling pathways, endocrine resistance, and targeted therapies
Proven Utility in Drug Discovery
- Widely used models such as MCF-7, T47D, and MDA-MB-231
- Applicable to high-throughput screening and pharmacogenomic studies
- Enable evaluation of hormone therapy, HER2-targeted agents, and novel compounds
FAQ
What types of breast tumor cell lines are included?
The collection includes a wide range of breast cancer cell lines representing major molecular subtypes such as luminal, HER2-positive, and triple-negative breast cancer, enabling diverse research applications.
How do I choose the right breast cancer cell line?
Selection depends on your research goals. Key considerations include:
- Hormone receptor status (ER/PR) and HER2 expression
- Molecular subtype and mutation profile
- Drug sensitivity, especially to endocrine or targeted therapies
- Experimental system requirements (2D vs. 3D models)
Do breast cancer cell lines reflect tumor heterogeneity?
Breast cancer is highly heterogeneous, and while individual cell lines represent specific subtypes, using a panel of models helps capture the diversity of tumor biology and treatment response.
Can these cell lines be used for endocrine therapy studies?
Yes, many luminal breast cancer cell lines are hormone-responsive and are widely used to study estrogen signaling and resistance to endocrine therapies such as tamoxifen and fulvestrant.
Are these cell lines suitable for targeted therapy research?
Yes, these models are commonly used to evaluate targeted therapies, including HER2 inhibitors, PI3K pathway inhibitors, and emerging treatments based on specific genetic alterations.
Are the cell lines authenticated and quality controlled?
All cell lines are STR-authenticated and routinely tested to ensure they are mycoplasma-free, supporting reliable and reproducible experimental outcomes.
How should breast tumor cell lines be stored and handled?
Cell lines are typically shipped as cryopreserved vials or on dry ice. Upon receipt, they should be stored in liquid nitrogen and maintained under standard cell culture conditions for optimal performance.